Topic Hub
144 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 144 of 144 clinical reviews.
A complete guide to Aetna (CVS Health) Farxiga coverage, prior authorization criteria, step therapy requirements, formulary tier placement, and how to appeal a denial in 2024.
Read clinical reviewA detailed guide to Anthem (Elevance Health) Farxiga coverage, including formulary tier, prior authorization criteria, step therapy requirements, appeal strategies, and cost-saving options for dapagliflozin.
Read clinical reviewA clinical and insurance guide to Farxiga coverage under Blue Cross Blue Shield Federated plans, including prior authorization criteria, step therapy requirements, formulary tiers, appeal strategies, and cost-reduction options.
Read clinical reviewCigna covers Farxiga (dapagliflozin) for type 2 diabetes, heart failure, and CKD with prior authorization. Learn the formulary tier, step therapy rules, PA criteria, and how to appeal a denial.
Read clinical reviewA detailed guide to Humana's formulary status for Farxiga (dapagliflozin), prior-authorization criteria, step-therapy requirements, appeal strategies, and cost-reduction options for 2024 to 2025.
Read clinical reviewA detailed guide to Kaiser Permanente formulary status, prior authorization criteria, step therapy requirements, and appeal strategies for Farxiga (dapagliflozin) covering type 2 diabetes, heart failure, and CKD indications.
Read clinical reviewMedicare Advantage plans generally cover Farxiga for type 2 diabetes, heart failure, and CKD under Part D formularies. Learn about prior authorization, step therapy, tier placement, appeals, and out-of-pocket costs.
Read clinical reviewA state-by-state guide to Medicaid coverage of Farxiga (dapagliflozin) for type 2 diabetes, heart failure, and CKD, including prior authorization criteria, step therapy requirements, formulary tiers, and how to appeal a denial.
Read clinical reviewA complete guide to TRICARE coverage of Farxiga (dapagliflozin) for type 2 diabetes, heart failure, and CKD, including formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
Read clinical reviewA complete guide to UnitedHealthcare coverage for Farxiga (dapagliflozin), including formulary tier, prior authorization criteria, step therapy requirements, appeals, and cost-saving options for type 2 diabetes, heart failure, and CKD.
Read clinical reviewEvidence-based guide to dapagliflozin (Farxiga) dosing in adolescents aged 12-17, covering FDA-approved indications, off-label pediatric use, clinical trial data, and monitoring protocols.
Read clinical reviewEvidence-based dapagliflozin dosing guide for adults aged 30, 49 covering type 2 diabetes, heart failure, and CKD indications with trial data, renal adjustments, and practical clinical advice.
Read clinical reviewMD-level guide to dapagliflozin drug-drug interactions, covering insulin, diuretics, lithium, digoxin, CYP/UGT metabolism, and clinical management strategies with PubMed-cited evidence.
Read clinical reviewFarxiga costs approximately $620/month at Alabama retail pharmacies in 2026. Learn about Alabama Medicaid coverage, insurance options, the AstraZeneca savings card, compounded dapagliflozin, and telehealth access.
Read clinical reviewCurrent Farxiga (dapagliflozin) pricing in Connecticut for 2026, including retail cash price, Medicaid coverage with prior authorization, insurance options, AstraZeneca savings card details, and compounded alternatives through 503A pharmacies.
Read clinical reviewFind out what Farxiga (dapagliflozin) costs in Delaware in 2026. Covers cash prices, Delaware Medicaid coverage, insurance options, the AstraZeneca savings card, compounded alternatives, and telehealth access.
Read clinical reviewCurrent Farxiga (dapagliflozin) pricing in District of Columbia for 2026. Covers DC Medicaid coverage, insurance options, the AstraZeneca savings card, compounded dapagliflozin legality, and telehealth access.
Read clinical reviewCurrent Farxiga (dapagliflozin) pricing in Florida for 2026, including cash-pay costs, Medicaid coverage status, insurance options, telehealth access, and AstraZeneca savings programs.
Read clinical reviewComplete 2026 guide to Farxiga (dapagliflozin) pricing in Georgia, including Medicaid coverage rules, insurance options, compounded alternatives, AstraZeneca savings cards, and telehealth access.
Read clinical reviewWhat Farxiga costs in Idaho in 2026, including cash prices, Idaho Medicaid coverage status, insurance options, compounded dapagliflozin access, and discount programs.
Read clinical reviewCurrent Farxiga pricing in Illinois for 2026, including cash-pay costs, Medicaid coverage with prior authorization, AstraZeneca savings cards, and compounded dapagliflozin options through 503A pharmacies.
Read clinical reviewWhat Farxiga costs in Indiana in 2026, including cash prices, Medicaid coverage, insurance options, compounded dapagliflozin, telehealth access, and discount programs.
Read clinical reviewCurrent Farxiga pricing in Louisiana for 2026, including cash-pay costs, Medicaid coverage status, private insurance tiers, the AstraZeneca savings card, compounded dapagliflozin, and telehealth access.
Read clinical reviewFind out what Farxiga (dapagliflozin) costs in Massachusetts in 2026, including retail pricing, Medicaid coverage, insurance options, manufacturer savings cards, and compounded alternatives.
Read clinical reviewFind out what Farxiga (dapagliflozin) costs in Michigan in 2026, including cash prices, Medicaid coverage, insurance options, discount programs, and compounded alternatives.
Read clinical reviewCurrent Farxiga pricing in Minnesota for 2026, including cash-pay costs, Minnesota Medicaid coverage, insurance options, the AstraZeneca savings card, and compounded dapagliflozin availability through 503A pharmacies.
Read clinical reviewCurrent Farxiga prices in Missouri for 2026, including cash-pay costs, Medicaid coverage rules, insurance options, AstraZeneca savings cards, and compounded dapagliflozin availability.
Read clinical reviewComplete guide to Farxiga (dapagliflozin) pricing in Montana for 2026, including cash-pay costs, Montana Medicaid coverage status, insurance options, manufacturer savings cards, and compounded alternatives.
Read clinical reviewCurrent Farxiga (dapagliflozin) pricing in Nebraska for 2026, including cash-pay costs, Nebraska Medicaid coverage status, insurance options, the AstraZeneca savings card, and compounded alternatives through 503A pharmacies.
Read clinical reviewCurrent Farxiga (dapagliflozin) pricing in New York for 2026, including cash-pay costs, Medicaid coverage, insurance options, manufacturer savings cards, and compounded alternatives.
Read clinical reviewFarxiga costs about $620/month at North Carolina retail pharmacies in 2026. Learn about NC Medicaid coverage, insurance options, the AstraZeneca savings card, compounded dapagliflozin, and telehealth access.
Read clinical reviewWhat Farxiga costs in Texas in 2026, including cash prices, Medicaid coverage, insurance options, manufacturer savings cards, and compounded dapagliflozin availability.
Read clinical reviewCurrent Farxiga pricing in Utah for 2026, including retail cost, Utah Medicaid coverage status, insurance options, AstraZeneca savings cards, compounded dapagliflozin access, and telehealth availability.
Read clinical reviewCurrent Farxiga pricing in Virginia for 2026, including cash-pay costs, Virginia Medicaid coverage with prior authorization, AstraZeneca savings cards, compounded dapagliflozin options, and telehealth access.
Read clinical reviewFarxiga costs about $620/month at Wyoming retail pharmacies in 2026. Learn about Wyoming Medicaid coverage, insurance options, the AstraZeneca savings card, and compounded dapagliflozin availability.
Read clinical reviewEvidence-based dapagliflozin dosing guide for young adults aged 18-29, covering type 2 diabetes, heart failure, and CKD indications with fertility and lifestyle considerations.
Read clinical reviewEvidence-based guide to dapagliflozin dosing in patients with liver disease, including mild, moderate, and severe hepatic impairment. FDA label data, pharmacokinetic studies, and clinical trial evidence reviewed.
Read clinical reviewEvidence-based guide to dapagliflozin dosing across stages of kidney disease. Covers FDA-approved eGFR thresholds, DAPA-CKD and DAPA-HF trial data, KDIGO recommendations, and when to initiate, continue, or stop Farxiga in renal impairment.
Read clinical reviewEvidence-based guide to dapagliflozin food and supplement interactions, including alcohol, high-sodium diets, diuretic herbs, and common supplements that affect SGLT2 inhibitor safety and efficacy.
Read clinical reviewComplete guide to dapagliflozin (Farxiga) dosing in older adults. Covers renal adjustments, fall risk, drug interactions, deprescribing, and clinical trial data from DAPA-HF and DAPA-CKD in patients 65 and older.
Read clinical reviewDapagliflozin (Farxiga) is an oral tablet, not an injection. Learn how this SGLT2 inhibitor works, proper dosing technique, and why it's prescribed for type 2 diabetes, heart failure, and chronic kidney disease.
Read clinical reviewA clinical deep-dive into how Farxiga (dapagliflozin) is manufactured, AstraZeneca's global supply chain, FDA shortage records, and the pharmacology behind this SGLT2 inhibitor.
Read clinical reviewEvidence-based guide to handling a missed dose of Farxiga (dapagliflozin). Covers timing rules, pharmacokinetics, clinical context for type 2 diabetes, heart failure, and CKD indications, plus physician-backed advice.
Read clinical reviewEvidence-based monitoring guide for adults aged 30 to 49 taking dapagliflozin (Farxiga), covering renal function, ketone awareness, genital infection screening, volume status, and lab timing.
Read clinical reviewEvidence-based monitoring guide for dapagliflozin (Farxiga) in adults aged 50 to 64, covering renal function, ketone awareness, volume status, and lab schedules drawn from DAPA-HF and ADA/KDIGO guidelines.
Read clinical reviewA clinician-reviewed guide to monitoring dapagliflozin (Farxiga) in young adults aged 18 to 29, covering baseline labs, follow-up intervals, fertility considerations, and red-flag symptoms.
Read clinical reviewEvidence-based monitoring protocol for dapagliflozin (Farxiga) in adolescents aged 12 to 17, covering renal labs, DKA surveillance, growth velocity, infection screening, and mental-health check-ins.
Read clinical reviewA clinician-grade review of dapagliflozin (Farxiga) off-label uses, ranked by evidence level. Covers obesity, MASLD, type 1 diabetes, polycystic kidney disease, gout, and more, with trial data and guideline citations.
Read clinical reviewEvidence-based guide to dapagliflozin (Farxiga) overdose management, covering pharmacokinetics, clinical presentation, treatment protocols, and prevention of accidental excess dosing.
Read clinical reviewEvidence-based monitoring guide for dapagliflozin (Farxiga) use in children under 12, covering off-label considerations, lab parameters, growth tracking, and safety signals clinicians should watch for.
Read clinical reviewDapagliflozin (Farxiga) is not FDA-approved for children under 12. This clinician-reviewed guide covers current evidence, off-label risks, SGLT2 inhibitor safety signals in pediatric populations, and what ongoing studies may reveal.
Read clinical reviewA physician-level review of dapagliflozin (Farxiga) real-world evidence from registries and observational studies spanning heart failure, CKD, and type 2 diabetes, with cited outcomes data from CVD-REAL, DECLARE, and DAPA-HF.
Read clinical reviewA comprehensive review of dapagliflozin (Farxiga/Forxiga) regulatory approvals across the US, EU, Canada, and UK, including approved indications for type 2 diabetes, heart failure, and chronic kidney disease, with key trial data and prescribing details.
Read clinical reviewEvidence-based safety profile of dapagliflozin (Farxiga) in adults aged 30 to 49, covering side effects, monitoring, genital infections, DKA risk, and real-world clinical guidance.
Read clinical reviewEvidence-based guide to dapagliflozin (Farxiga) safety in geriatric patients 65+, covering renal considerations, hypotension risk, fracture data, drug interactions, and deprescribing strategies.
Read clinical reviewEvidence-based safety profile of dapagliflozin (Farxiga) in adults aged 50-64, covering cardiovascular benefits, renal protection, genital infections, volume depletion, and DKA risk with clinical trial data.
Read clinical reviewA clinical review of dapagliflozin (Farxiga) safety data specific to young adults aged 18 to 29, covering side effects, fertility considerations, and monitoring recommendations.
Read clinical reviewA physician-reviewed guide to dapagliflozin (Farxiga) safety in adolescents aged 12 to 17, covering FDA approval history, clinical trial data, DKA risk, growth monitoring, and dosing guidance.
Read clinical reviewFarxiga (dapagliflozin) costs around $620/month cash-pay at Alaska pharmacies in 2026. Alaska Medicaid does not cover it. Learn every savings path, from AstraZeneca's patient program to compounded dapagliflozin via 503A pharmacies, with physician-reviewed guidance.
Read clinical reviewA complete 2026 guide to dapagliflozin (Farxiga) pricing in Arkansas, including Medicaid prior authorization rules, AstraZeneca savings programs, compounded dapagliflozin legality via 503A pharmacies, and telehealth access.
Read clinical reviewShowing the first 60 matches. Use search or filters to narrow the library.